Last reviewed · How we verify
NCT06587737: CoVasc-ICH2
Colchicine for the Reduction of Dependency and Vascular Events After an Acute Intracerebral Hemorrhage
Phase 3 trial testing Colchicine 0.5 MG in Colchicine in 1,125 participants. Not yet recruiting.
30 July 2028
Quick facts
| Lead sponsor | Population Health Research Institute |
|---|---|
| Phase | Phase 3 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 1,125 |
| Start date | 30 May 2026 |
| Primary completion | 30 July 2028 |
| Estimated completion | 30 October 2028 |
Drugs / interventions tested
- Colchicine 0.5 MG — full drug profile →
- Placebo
Conditions studied
- Colchicine — all drugs for Colchicine →
- ICH - Intracerebral Hemorrhage — all drugs for ICH - Intracerebral Hemorrhage →
- Stroke — all drugs for Stroke →
- Dependence — all drugs for Dependence →
Sponsor
Population Health Research Institute
Who can join
18 and older, any sex, with Colchicine or ICH - Intracerebral Hemorrhage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Data indicate that patients with intracerebral hemorrhage (ICH) are at high risk for thromboembolic events and disability that is not being sufficiently mitigated by current treatment strategies. This is aggravated by the cessation of antithrombotic medications for significant periods after hemorrhage. These findings highlight the need for novel treatments that modify the high risk for major vascular events and functional outcomes in ICH survivors. The objective of CoVasc-ICH 2 is to demonstrate that oral colchicine 0.5 mg daily is superior to placebo for improving the outcomes of ICH survivors with evidence or risk factors for atherosclerosis, when started within 72 hours from ICH onset.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
European Stroke Organisation (ESO) and European Association of Neurosurgical Societies (EANS) guideline on stroke due to spontaneous intracerebral haemorrhage.
Steiner T, Purrucker JC, Aguiar de Sousa D, Apostolaki-Hansson T, et al · · 2025 · cited 41× · PMID 40401775 · DOI 10.1177/23969873251340815 -
Therapeutic strategies in intracerebral hemorrhage: from hematoma stabilization to alleviating secondary brain injury.
Hsieh PF, Liu YB, Cordonnier C, Tsai HH. · · 2026 · PMID 42027301 · DOI 10.1016/j.rpth.2026.103423 -
ESO annual stroke evidence update 2025.
de Sousa DA, Katsanos AH, Li L, Martinez-Majander N, et al · · 2026 · PMID 41706824 · DOI 10.1093/esj/aakag009
Verify or expand the search:
- PubMed search for NCT06587737
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Colchicine 0.5 MG
Trials testing the same drug.
- NCT06798714 — The Effect of Colchicine on the Occurrence of Atrial Fibrillation After Cardiac Surgery · Phase 4 · recruiting
- NCT06469528 — ESCALATion of Medical Therapy Following Multimodality Plaque Evaluation in High-risk Chronic Coronary Syndromes · Phase 3 · not yet recruiting
- NCT06118034 — Effect of Colchicine on Perioperative Anti-inflammatory Organ Injury in Cardiac Surgery · Phase 3 · recruiting
- NCT06078904 — Different Doses of Colchicine on hsCRP · Phase 4 · completed
- NCT05476991 — Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atheros · Phase 3 · recruiting
Other recruiting trials for Colchicine
Currently open trials in the same condition.
- NCT06798714 — The Effect of Colchicine on the Occurrence of Atrial Fibrillation After Cardiac Surgery · Phase 4 · recruiting
- NCT06472908 — Efficacy and Safety of Colchicine After PCI · Phase 3 · recruiting
- NCT05637398 — Colchicine in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction · Phase 1, PHASE2 · recruiting
Other Population Health Research Institute trials
Trials by the same sponsor.
- NCT07511543 — Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy · Phase 2 · not yet recruiting
- NCT07468448 — Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe · Phase 3 · not yet recruiting
- NCT07011095 — DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial · EARLY_PHASE1 · not yet recruiting
- NCT06508164 — International CRDS Registry · recruiting
- NCT06486636 — Pericardiotomy in Cardiac Surgery · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06587737 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Population Health Research Institute
- Last refreshed: 25 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06587737.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing